全文获取类型
收费全文 | 23189篇 |
免费 | 1120篇 |
国内免费 | 121篇 |
专业分类
耳鼻咽喉 | 325篇 |
儿科学 | 339篇 |
妇产科学 | 470篇 |
基础医学 | 2953篇 |
口腔科学 | 598篇 |
临床医学 | 1735篇 |
内科学 | 6361篇 |
皮肤病学 | 251篇 |
神经病学 | 1729篇 |
特种医学 | 669篇 |
外科学 | 3986篇 |
综合类 | 103篇 |
一般理论 | 1篇 |
预防医学 | 688篇 |
眼科学 | 342篇 |
药学 | 1582篇 |
中国医学 | 42篇 |
肿瘤学 | 2256篇 |
出版年
2022年 | 168篇 |
2021年 | 382篇 |
2020年 | 219篇 |
2019年 | 255篇 |
2018年 | 375篇 |
2017年 | 281篇 |
2016年 | 350篇 |
2015年 | 361篇 |
2014年 | 512篇 |
2013年 | 643篇 |
2012年 | 975篇 |
2011年 | 1051篇 |
2010年 | 572篇 |
2009年 | 520篇 |
2008年 | 1021篇 |
2007年 | 1083篇 |
2006年 | 1029篇 |
2005年 | 964篇 |
2004年 | 967篇 |
2003年 | 951篇 |
2002年 | 990篇 |
2001年 | 890篇 |
2000年 | 930篇 |
1999年 | 798篇 |
1998年 | 291篇 |
1997年 | 216篇 |
1996年 | 197篇 |
1995年 | 178篇 |
1994年 | 157篇 |
1993年 | 138篇 |
1992年 | 597篇 |
1991年 | 625篇 |
1990年 | 532篇 |
1989年 | 539篇 |
1988年 | 520篇 |
1987年 | 497篇 |
1986年 | 427篇 |
1985年 | 428篇 |
1984年 | 314篇 |
1983年 | 238篇 |
1979年 | 232篇 |
1978年 | 132篇 |
1977年 | 136篇 |
1974年 | 128篇 |
1973年 | 119篇 |
1972年 | 137篇 |
1971年 | 127篇 |
1970年 | 114篇 |
1969年 | 137篇 |
1967年 | 128篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
991.
992.
993.
Christina Andica Koji Kamagata Taku Hatano Yuya Saito Wataru Uchida Takashi Ogawa Haruka Takeshige-Amano Akifumi Hagiwara Syo Murata Genko Oyama Yashushi Shimo Atsushi Umemura Toshiaki Akashi Akihiko Wada Kanako K. Kumamaru Masaaki Hori Nobutaka Hattori Shigeki Aoki 《Journal of neuroscience research》2020,98(5):936-949
Neurocognitive and psychiatric disorders have significant consequences for quality of life in patients with Parkinson's disease (PD). In the current study, we evaluated microstructural white matter (WM) alterations associated with neurocognitive and psychiatric disorders in PD using neurite orientation dispersion and density imaging (NODDI) and linked independent component analysis (LICA). The indices of NODDI were compared between 20 and 19 patients with PD with and without neurocognitive and psychiatric disorders, respectively, and 25 healthy controls using tract-based spatial statistics and tract-of-interest analyses. LICA was applied to model inter-subject variability across measures. A widespread reduction in axonal density (indexed by intracellular volume fraction [ICVF]) was demonstrated in PD patients with and without neurocognitive and psychiatric disorders, as compared with healthy controls. Compared with patients without neurocognitive and psychiatric disorders, patients with neurocognitive and psychiatric disorders exhibited more extensive (posterior predominant) decreases in axonal density. Using LICA, ICVF demonstrated the highest contribution (59% weight) to the main effects of diagnosis that reflected widespread decreases in axonal density. These findings suggest that axonal loss is a major factor underlying WM pathology related to neurocognitive and psychiatric disorders in PD, whereas patients with neurocognitive and psychiatric disorders had broader axonal pathology, as compared with those without. LICA suggested that the ICVF can be used as a useful biomarker of microstructural changes in the WM related to neurocognitive and psychiatric disorders in PD. 相似文献
994.
Tatsuaki Takeda Hiromasa Yamamoto Ken Suzawa Shuta Tomida Shunsaku Miyauchi Kota Araki Kentaro Nakata Akihiro Miura Kei Namba Kazuhiko Shien Junichi Soh Tadahiko Shien Yoshihisa Kitamura Toshiaki Sendo Shinichi Toyooka 《Cancer science》2020,111(3):849-856
Molecular‐targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are evolving for various cancers. Neratinib is an irreversible pan‐HER tyrosine kinase inhibitor and has been approved by the FDA as an effective drug for HER2‐positive breast cancer. However, acquired resistance of various cancers to molecular‐targeted drugs is an issue of clinical concern, and emergence of resistance to neratinib is also considered inevitable. In this study, we established various types of neratinib‐resistant cell lines from HER2‐amplified breast and lung cancer cell lines using several drug exposure conditions. We analyzed the mechanisms of emergence of the resistance in these cell lines and explored effective strategies to overcome the resistance. Our results revealed that amplification of YES1, which is a member of the SRC family, was amplified in two neratinib‐resistant breast cancer cell lines and one lung cancer cell line. Knockdown of YES1 by siRNA and pharmacological inhibition of YES1 by dasatinib restored the sensitivity of the YES1‐amplified cell lines to neratinib in vitro. Combined treatment with dasatinib and neratinib inhibited tumor growth in vivo. This combination also induced downregulation of signaling molecules such as HER2, AKT and MAPK. Our current results indicate that YES1 plays an important role in the emergence of resistance to HER2‐targeted drugs, and that dasatinib enables such acquired resistance to neratinib to be overcome. 相似文献
995.
996.
Tatsuki Ueda Ayako Kumagai Shoichi Iriguchi Yutaka Yasui Tadayo Miyasaka Kengo Nakagoshi Kazuki Nakane Keigo Saito Mari Takahashi Aki Sasaki Shinsuke Yoshida Naoko Takasu Hiroshi Seno Yasushi Uemura Koji Tamada Tetsuya Nakatsura Shin Kaneko 《Cancer science》2020,111(5):1478-1490
The use of allogeneic, pluripotent stem‐cell‐derived immune cells for cancer immunotherapy has been the subject of recent clinical trials. In Japan, investigator‐initiated clinical trials will soon begin for ovarian cancer treatment using human leukocyte antigen (HLA)‐homozygous‐induced pluripotent stem cell (iPSC)‐derived anti–glypican‐3 (GPC3) chimeric antigen receptor (CAR)‐expressing natural killer/innate lymphoid cells (NK/ILC). Using pluripotent stem cells as the source for allogeneic immune cells facilitates stringent quality control of the final product, in terms of efficacy, safety and producibility. In this paper, we describe our methods for the stable, feeder‐free production of CAR‐expressing NK/ILC cells from CAR‐transduced iPSC with clinically relevant scale and materials. The average number of cells that could be differentiated from 1.8‐3.6 × 106 iPSC within 7 weeks was 1.8‐4.0 × 109. These cells showed stable CD45/CD7/CAR expression, effector functions of cytotoxicity and interferon gamma (IFN‐γ) production against GPC3‐expressing tumor cells. When the CAR‐NK/ILC cells were injected into a GPC3‐positive, ovarian‐tumor‐bearing, immunodeficient mouse model, we observed a significant therapeutic effect that prolonged the survival of the animals. When the cells were injected into immunodeficient mice during non–clinical safety tests, no acute systemic toxicity or tumorigenicity of the final product or residual iPSC was observed. In addition, our test results for the CAR‐NK/ILC cells generated with clinical manufacturing standards are encouraging, and these methods should accelerate the development of allogeneic pluripotent stem cell‐based immune cell cancer therapies. 相似文献
997.
Yu Akazawa Yuki Saito Toshiaki Yoshikawa Keigo Saito Kazuto Nosaka Manami Shimomura Shoichi Mizuno Yasunari Nakamoto Tetsuya Nakatsura 《Cancer science》2020,111(8):2736-2746
Lung cancer is the leading cause of cancer‐related deaths worldwide. Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKI) often have good clinical activity against non–small cell lung cancer (NSCLC) with activating EGFR mutations. Osimertinib, which is a third‐generation EGFR‐TKI, has a clinical effect even on NSCLC harboring the threonine to methionine change at codon 790 of EGFR (EGFR T790M) mutation that causes TKI resistance. However, most NSCLC patients develop acquired resistance to osimertinib within approximately 1 year, and 40% of these patients have the EGFR T790M and cysteine to serine change at codon 797 (C797S) mutations. Therefore, there is an urgent need for the development of novel treatment strategies for NSCLC patients with the EGFR T790M/C797S mutation. In this study, we identified the EGFR T790M/C797S mutation‐derived peptide (790‐799) (MQLMPFGSLL) that binds the human leukocyte antigen (HLA)‐A*02:01, and successfully established EGFR T790M/C797S‐peptide‐specific CTL clones from human PBMC of HLA‐A2 healthy donors. One established CTL clone demonstrated adequate cytotoxicity against T2 cells pulsed with the EGFR T790M/C797S peptide. This CTL clone also had high reactivity against cancer cells that expressed an endogenous EGFR T790M/C797S peptide using an interferon‐γ (IFN‐γ) enzyme‐linked immunospot (ELISPOT) assay. In addition, we demonstrated using a mouse model that EGFR T790M/C797S peptide‐specific CTL were induced by EGFR T790M/C797S peptide vaccine in vivo. These findings suggest that an immunotherapy targeting a neoantigen derived from EGFR T790M/C797S mutation could be a useful novel therapeutic strategy for NSCLC patients with EGFR‐TKI resistance, especially those resistant to osimertinib. 相似文献
998.
999.
1000.
Kohei Saito Tatsuhide Inoue Hiroyuki Ariyasu Toshio Shimada Hiroshi Itoh Issei Tanaka Chikashi Terao 《Journal of diabetes investigation.》2022,13(4):706
Aims/IntroductionWe aimed to replicate a new diabetes subclassification based on objective clinical information at admission in a diabetes educational inpatient program. We also assessed the educational outcomes for each cluster.MethodsWe included diabetes patients who participated in the educational inpatient program during 2009–2020 and had sufficient clinical information for the cluster analysis. We applied a data‐driven clustering method proposed in a previous study and further evaluated the clinical characteristics of each cluster. We investigated the association between the clusters and changes in hemoglobin A1c level from the start of the education program. We also assessed the risk of re‐admission for the educational program.ResultsWe divided a total of 651 patients into five clusters. Their clinical characteristics followed the same pattern as in previous studies. The intercluster ranking of the cluster center coordinates showed strong correlation coefficients with those of the previous studies (mean ρ = 0.88). Patients classified as severe insulin‐resistant diabetes (cluster 3) showed a more pronounced progression of renal dysfunction than patients classified as the other clusters. The patients classified as severe insulin‐deficient diabetes (cluster 2) had the highest rate of reduction in hemoglobin A1c level from the start of the program (P < 0.01) and a tendency toward a lower risk of re‐admission for the education program (hazard ratio 0.47, P = 0.09).ConclusionWe successfully replicated the diabetes subclassification using objective clinical information at admission for the education program. In addition, we showed that severe insulin‐deficient diabetes patients tended to have better educational outcomes than patients classified as the other clusters. 相似文献